{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:57:22Z","timestamp":1770969442712,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1136\/ard.2008.092734","type":"journal-article","created":{"date-parts":[[2008,10,2]],"date-time":"2008-10-02T00:35:27Z","timestamp":1222907727000},"page":"930-937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group"],"prefix":"10.1016","volume":"68","author":[{"given":"M T","family":"Halpern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"Cifaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T K","family":"Kvien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2008.092734_bib1","first-page":"499","article-title":"Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002\u20132003","volume":"24","author":"Hanova","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1136\/ard.2008.092734_bib2","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1186\/ar578","article-title":"Epidemiology and genetics of rheumatoid arthritis","volume":"4","author":"Silman","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1136\/ard.2008.092734_bib3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/rheumatology\/41.7.793","article-title":"The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century","volume":"41","author":"Symmons","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.092734_bib4","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/art.1780381002","article-title":"The economic cost and social psychological impact of musculoskeletal conditions","volume":"38","author":"Yelin","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib5","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ard.2008.092734_bib6","first-page":"891","article-title":"Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case","volume":"30","author":"Maetzel","year":"2003","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1136\/ard.2008.092734_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/rheumatology\/keaa489","article-title":"The 'side effects\u2019 of rheumatoid arthritis: joint destruction, disability, and early mortality","volume":"32","author":"Pincus","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2008.092734_bib8","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/art.11024","article-title":"Predicting mortality in patients with rheumatoid arthritis","volume":"48","author":"Wolfe","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib9","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/1529-0131(200112)44:12<2746::AID-ART461>3.0.CO;2-Z","article-title":"Long-term morbidity, mortality and economics of rheumatoid arthritis","volume":"44","author":"Wong","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P","article-title":"Economic consequences of the progression of rheumatoid arthritis in Sweden","volume":"42","author":"Kobelt","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib11","first-page":"505","article-title":"A multicenter cost-of-illness study on rheumatoid arthritis in Italy","volume":"20","author":"Leardini","year":"2002","journal-title":"Clin Exp Rheumatol"},{"issue":"44","key":"10.1136\/ard.2008.092734_bib12","first-page":"47","article-title":"The costs of rheumatoid arthritis: absolute, incremental and marginal estimates","volume":"23","author":"Yelin","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.092734_bib13","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1017\/S0266462300103228","article-title":"Socioeconomic costs of rheumatic diseases. Implications for technology assessment","volume":"16","author":"Jonsson","year":"2000","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1136\/ard.2008.092734_bib14","unstructured":"Schmidt A, Husberg M, Bernfort L. Socioeconomic costs for rheumatic disease. CMT Rapport 2003:5. Link\u00f6ping: Centre for Medical Technology Assessment, Link\u00f6ping University, Sweden [in Swedish]."},{"key":"10.1136\/ard.2008.092734_bib15","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/rheumatology\/keh324","article-title":"Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project)","volume":"43","author":"Hallert","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.092734_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/rheumatology\/kei157","article-title":"Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project)","volume":"45","author":"Hallert","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.092734_bib17","first-page":"1068","article-title":"Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis","volume":"26","author":"Clarke","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.092734_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.1780290405","article-title":"A multicenter study of annual health service utilization and costs in rheumatoid arthritis","volume":"29","author":"Lubeck","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib19","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/1529-0131(200103)44:3<528::AID-ANR100>3.0.CO;2-U","article-title":"Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease","volume":"44","author":"Merkesdal","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/1529-0131(199906)42:6<1209::AID-ANR18>3.0.CO;2-M","article-title":"An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline","volume":"42","author":"Yelin","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/03009740510018633","article-title":"Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register","volume":"34","author":"Odegard","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard.2008.092734_bib22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01.mlr.0000204257.25875.04","article-title":"The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work","volume":"44","author":"Li","year":"2006","journal-title":"Med Care"},{"key":"10.1136\/ard.2008.092734_bib23","first-page":"849","article-title":"Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis","volume":"31","author":"Kavanaugh","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.092734_bib24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.7326\/0003-4819-134-8-200104170-00013","article-title":"Rational use of new and existing disease-modifying agents in rheumatoid arthritis","volume":"138","author":"Kremer","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2008.092734_bib25","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib26","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.2008.092734_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.092734_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/occmed\/kqi171","article-title":"Systematic review of studies of productivity loss due to rheumatoid arthritis","volume":"56","author":"Burton","year":"2006","journal-title":"Occup Med (Lond)"},{"key":"10.1136\/ard.2008.092734_bib30","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/art.11285","article-title":"Association between etanercept use and employment outcomes among patients with rheumatoid arthritis","volume":"48","author":"Yelin","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1136\/ard.2008.092734_bib31","first-page":"i103","article-title":"Adalimumab-treated patients with long-standing rheumatoid arthritis (RA) decrease their resource utilization during the course of long-term treatment","volume":"46","author":"Mittendorf","year":"2007","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2008.092734_bib32","first-page":"2288","article-title":"A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-\u03b1 antibody adalimumab (D2E7) in patients with rheumatoid arthritis","volume":"29","author":"den Broeder","year":"2002","journal-title":"J Rheumatol"},{"issue":"(Suppl","key":"10.1136\/ard.2008.092734_bib33","first-page":"S55","article-title":"Long term efficacy and tolerability of multiple IV doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis [abstract]","volume":"41","author":"Rau","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"(Suppl","key":"10.1136\/ard.2008.092734_bib34","first-page":"S57","article-title":"Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis\u2014results of a Phase I study","volume":"41","author":"Schattenkirchner","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib35","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2003.009563","article-title":"Efficacy and safety of the fully human anti-tumour necrosis factor monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study","volume":"62","author":"van de Putte","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.092734_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/03009740410005467","article-title":"Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate","volume":"33","author":"Rau","year":"2004","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard.2008.092734_bib37","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","article-title":"Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed","volume":"63","author":"van de Putte","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"39","key":"10.1136\/ard.2008.092734_bib38","first-page":"188","article-title":"A Norwegian DMARD register: Prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases","volume":"23","author":"Kvien","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2008.092734_bib39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0950-3579(97)80032-5","article-title":"Evaluation of early rheumatoid arthritis disease activity and outcome","volume":"11","author":"van Gestel","year":"1997","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1136\/ard.2008.092734_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2007.03.003","article-title":"Biological and clinical effects of anti-TNF alpha treatment","volume":"7","author":"Valesini","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard.2008.092734_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clim.2007.08.013","article-title":"TNF alpha blockade in human diseases: mechanisms and future directions","volume":"126","author":"Wong","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1136\/ard.2008.092734_bib44","first-page":"46","article-title":"The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis","volume":"72","author":"Haraoui","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"10.1136\/ard.2008.092734_bib45","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1517\/14712598.6.12.1349","article-title":"Adalimumab for rheumatoid arthritis","volume":"6","author":"Voulgari","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1136\/ard.2008.092734_bib46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/art.21548","article-title":"Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients","volume":"54","author":"Odegard","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"II","key":"10.1136\/ard.2008.092734_bib47","first-page":"650","article-title":"Impact of adalimumab (HUMIRA\u00ae) combination therapy on expected resource use by patients with early rheumatoid arthritis: results from a companion study to PREMIER [abstract]","volume":"67","author":"van Vollenhoven","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.092734_bib48","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1592\/phco.25.3.352.61594","article-title":"Validation of an insulin infusion nomogram for intensive glucose control in critically ill patients","volume":"25","author":"Chant","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1136\/ard.2008.092734_bib49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00003086-199712000-00021","article-title":"Effect of a patient management system on outcomes of total hip and knee arthroplasty","volume":"345","author":"Fisher","year":"1997","journal-title":"Clin Orthop Relat Res"},{"key":"10.1136\/ard.2008.092734_bib50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ajhp\/62.4.391","article-title":"Cyclosporine-sparing effects of daclizumab in renal allograft recipients","volume":"62","author":"Ingle","year":"2005","journal-title":"Am J Health-System Pharm"},{"key":"10.1136\/ard.2008.092734_bib51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1183\/09031936.94.07020260","article-title":"Plasma concentration of elastase-alpha 1-proteinase inhibitor complex in surfactant-treated preterm neonates with respiratory distress syndrome","volume":"7","author":"Tegtmeyer","year":"1994","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1136\/ard.2008.092734_bib52","doi-asserted-by":"crossref","first-page":"iv18","DOI":"10.1093\/rheumatology\/kei056","article-title":"Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness","volume":"44","author":"Wolfe","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.092734_bib53","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.22097","article-title":"Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial","volume":"55","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib54","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/art.21661","article-title":"Infliximab treatment maintains employability in patients with early rheumatoid arthritis","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib55","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/art.11436","article-title":"Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial","volume":"50","author":"Puolakka","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.092734_bib56","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/ard.2003.019034","article-title":"Predictors of productivity loss in early rheumatoid arthritis: a 5-year follow-up study","volume":"64","author":"Puolakka","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.092734_bib57","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/ard.2005.048439","article-title":"Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US","volume":"65","author":"Chung","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.092734_bib58","first-page":"1726","article-title":"Intranasal administration of recombinant human cartilage glycoprotein-39. A phase I escalating cohort study in patients with rheumatoid arthritis","volume":"33","author":"Zandbelt","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.092734_bib59","unstructured":"Statistics Norway. Focus on wages. http:\/\/www.ssb.no\/english\/subjects\/06\/lonn_en\/ (accessed 18 Dec 2006)."},{"key":"10.1136\/ard.2008.092734_bib60","unstructured":"Universal Currency Converter. http:\/\/www.oanda.com (accessed 18 Dec 2006)."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724217647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724217647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2008.092734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:50:11Z","timestamp":1739523011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724217647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0003496724217647"],"URL":"https:\/\/doi.org\/10.1136\/ard.2008.092734","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2008.092734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 \u00a9 Halpern et al 2009, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}